GlassScriptPhysician profile
Dana Williams
NPI 1760071492
$4,597.56
in general payments reported to CMS, 2019-2025
24 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.09 · 2022: $1,540 · 2023: $1,958 · 2024: $502 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937 · Consulting Fee: $54.00 · Education: $44.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.18 |
| Consulting Fee | $54.00 |
| Education | $44.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,346.50 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $732.95 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $731.27 | 2022-2024 | Tezspire, Fasenra, Airsupra |
| Biocryst US Sales Co., LLC | $299.49 | 2022-2025 | Orladeyo |
| Amgen INC. | $207.84 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $156.37 | 2023-2024 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $149.44 | 2022-2024 | Hyqvia, Takhzyro |
| Pfizer INC. | $147.91 | 2022-2025 | |
| Kaleo, INC. | $140.69 | 2022-2024 | Auvi-Q |
| Csl Behring | $107.45 | 2022-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $86.25 | 2025 | |
| Aytu Biopharma, INC. | $71.87 | 2022-2023 | Karbinal |
| Teva Pharmaceuticals USA, INC. | $56.71 | 2022 | |
| Adma Biomanufacturing LLC | $54.00 | 2025 | |
| Abbvie INC. | $51.55 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.06 | 2024 | |
| Vapotherm INC | $43.59 | 2022 | |
| Optinose US, INC. | $37.84 | 2022-2024 | |
| Pharming Healthcare, INC. | $30.86 | 2023-2024 | Ruconest |
| Octapharma USA, INC. | $24.17 | 2022 | |
| Insulet Corporation | $22.09 | 2021 | |
| Hikma Pharmaceuticals USA | $18.42 | 2023 | Ryaltris |
| Incyte Corporation | $17.36 | 2024 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $16.88 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.